Tonix to develop candidate as potential treatment for Long COVID Syndrome damircudic/E+ via Getty Images Tonix Pharmaceuticals(NASDAQ:TNXP)will develop TNX-102 SL, currently in phase 3 development for fibromyalgia, as apotential treatment for Long COVID Syndrome. The disease's symptoms include pain, sleep disturbance, fatigue, and brain fog, which are also seen in fibromyalgia. Tonix plans to meet with the FDA in Q3 to determine the design of a pivotal phase 2 study. Some studies have indicated that Long COVID Syndrome, officially called Post-Acute Sequelae of COVID-19 ("PASC"), can occur in more than 30% of COVID-19 patients that have recovered. Tonix shares are up 1.6% to $1.24 in premarket trading.
HA HA HA HA Microstrategy buys another 13K bitcoins for nearly $500M JUST BEFORE IT PLUNGES-! Joe Raedle RECEIVING THE NEWS THAT BITCOIN IS DOWN HUGE Microstrategy(NASDAQ:MSTR)quickly puts the funds from its recent junk bond sale to work,announcing the purchaseof 13,005 bitcoins (BTC-USD) for $489M, or an average price of $37,617 each. THE SEC NEEDS TO GET INVOLVED COMPANIES SHOULD NOT BE ALLOWED TO DO THIS TO THEIR SHARE HOLDERS NO MATTER HOW STUPID THEY MAY BE.
BREAKING NEWS REVG REV Group $14.95 -0.245(-1.61%) 06/08/21 Baird REV Group price target raised to $25 from $22 at Baird 06/08/21 Baird REV Group demand and operating momentum still building, says Baird Clear This Search Over a week ago Show Full Stories Send Info REV Group CEO sells nearly 20,000 common shares 06/11<----------------- REVG In a regulatory filing, REV Group CEO Rodney Rushing disclosed the sale of 19,292 common shares of the company on June 11 at a price of $15.87 per share. ShowRelated Items >> REV Group 5.5M share Secondary priced at $15.50 »06/10 REVG The deal size was reduced… REV Group falls -8.5% »06/10 REVG REV Group is down -8.5%,… REV Group announces offering of 7.5M shares of common stock for holders »06/09 REVG REV Group announced the… REV Group price target raised to $25 from $22 at Baird 06/08 REVG Baird analyst Mircea Dobre raised the firm's price target on REV Group to $25 from $22 and keeps an Outperform rating on the shares. Dobre said that operational improvement combines with broader end-market tailwinds as orders increased sequentially across the board. The analyst added that execution is improving at a faster pace than embedded in management's fiscal 2023 targets. Analysts do seem to like it Van but that secondary was sloppy not a good sign.
CAPTAIN A WHALE BREACHES YONDER! THE EYE! THE EYE! BUY BUY BUY!!! LETS RUN THIS GOED ROBIN HOOD 1847 Goedeker Inc. (GOED) SHE WANTS MORE! NYSE American - Nasdaq Real Time Price. Currency in USD Add to watchlist 3.7805+0.4505 (+13.5285%)<----------- As of 10:25AM EDT. Market open.